Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Rodman & Renshaw (September 2009)
22 slides from Lisata Therapeutics's conference presentation, Sep 9, 2009
Slide 1: NeoStem
NeoStem. Robin Smith, MD, MBA Chairman & CEO Rodman & Renshaw September 9, 2009 (NYSE AMEX: NBS)
Slide 2: Forward Looking Statements
Forward Looking Statements set nd 0) Torre at i tg unde Search or Company Flings Proposed Merger: Independent China Expansion Aves ‘2 {ort year nda vcore’ 3,200 ara ote opr fed wh he SEC
Slide 3: NeoStem Summary
NeoStem Summary Listed on the NYSE AMEX (ticker: NBS) Have completed approximately $32 Million in financing through June 2009 Leading a of commercial autologous adult stem cell bank ° collection, and long-term storage of stem cells rom 2 adult donors for their own future medical treatment Growing Ne
Slide 4: NeoStem Summary (continued)
NeoStem Summary cntinuea) = Shift toward development therapeutics o Worldwide exclusive license from and continuing collaboration with University of Louisville on VSEL Technology (VSEL very small embryonic like stem cells, found in individuals, may contain many physical characteristics typically fou
Slide 5: Current Revenue Model
Current Revenue Model Collection center fees Collection and processing fees from patients Storage fees (recurring revenue) Usage Fees Licensing of our technologies abroad Nessiem
Slide 6: Growth Drivers for the Collection Business
Growth Drivers for the Collection Business Heart Disease “It saved my life... my own stem cel BERNIE ‘Adult Stem Cll Heart Recipient Lupus “My Lupus has been in remission for more than 5 years..” Katy ‘Adult Stem Cell Recipient Multiple Sclerosis a4 “Stem Cells helped me walk again.” Janice ‘Adult S
Slide 7: Future Stem Cell Therapies
Future Stem Cell Therapies Over 2,000 Adult Stem Cell Clinical Trials = By 2017 it’s forecasted that a minimum of 16 stem cells products will be approved through the FDA and used in 1.9 million annual procedures.* Autoimmune Diabetes/Metabolic Cardiovascular Orthopedic 0000 Non- Closing Fracture 2Mo
Slide 8: NeoStem's Accessing Therapeutic Marketplace Through Licensing Arrangements
NeoStem’s Accessing Therapeutic Marketplace Through Licensing Arrangements Wound Care: © Vincent Falanga © Composition and Methods Using Stem Cells in Cutaneous Wound Healing Skin Rejuvenation: © Vincent Giampapa © Methad and Composition for Restoration of Age-Related Tissue Loss in he Face or Selec
Slide 9: Very-Small Embryonic-like Stem Cells (VSELs)
Very-Small Embryonic-like Stem Cells (VSELs) (— NeoStem's research and development activities are focused on the repair, mi ‘aging and other regenerative medicine applicat TZ unpuritied 8 MING BE CXCR#* CD84* ACIS" Lin CD45: MRNA (log-fold difference)
Slide 10: NeoStem Stem Cells Collection Process
NeoStem Stem Cells Collection Process Each of us has a population of very primitive embryonic like stem cells that have remained in our bodies since birth =Can be mobilized in the blood using NeoStem Process =Should be easily recovered =Cryopreserved =Used for future therapeutic applications. NeeSie
Slide 11: Next Steps
NeoStem® Next Steps NeeSiem
Slide 12: CBH Acquisition
CBH Acquisition ‘Cosmetic /Anti- aging CBH’s Pharma revenues and earnings provide certain stability that should be able to underpin the stem cell rollout NBS brings innovative stem cell technology as well as credibility domain knowledge which will be a platform for expansion into shina 0°. Ne@Stem
Slide 13: Why Is China Bio Acquisition So Significant
Why Is China Bio Acquisition So Significant = China’s annual drug bill is $73 billion, 45% of total health care expenditures, which is double that of the international average. China’s Health care reform projected to increase the national pharmaceutical market by annual growth rate of 22%, from $24.
Slide 14: Suzhou Erye Pharmaceutical
Suzhou Erye Pharmaceutical Pen, signed agreement to acquire 51% ownership in Suzhou Erye Company in 2008**. Form S-4 Registration rSetonont filled in July 2009. Anticipated Close before end of 2009. Historically Consistent increase in Pharma revenues and earnings Provides a stronger balance sheet an
Slide 15: Competitive Landscape China
Competitive Landscape China Other China Pharma Companies trade at Avg. 86.6x Current P/E Comps Analysis - CBH ‘Share Price MktCap EPS PIE Name. Exchange Country Industry _(USD)_(USD)_2008_~ Gurrent_2008 Minsheng Investment Management Co,, Inc. China China_Pharmaceuticals $1.08 $551.70 ($0.03) 68.80x
Slide 16: Stem Cell Initiatives in PRC
Stem Cell Initiatives in PRC Partnership with leading hospitals and PRC governmental agencies - Translational R&D (Beijing Laboratory) - R&D grant - Clinical trials for selected indications - Commercial roll out of selected therapies (orthopedic, anti-aging cosmetic) Initial offices established in B
Slide 17: Current Capitalization
Current Capitalization August 18, 2009 of Shares Preferred stock; (authorized 5,000,000 shares) Series B convertible preferred stock 10,000 (authorized 825,000 shares) Series D convertible preferred stock. 1,293,251 (authorized 1,293,251 shares*) ‘Common stock 8,538,848, (authorized $00,000,000 shar
Slide 18: Post Merger Capitalization
Post Merger Capitalization Series C convertible preferred stock (authorized 8,177,512 shares) K authorized 500,000,000 shares) Warrants Outstanding, Series E Warrants US Stock Options Outstanding Non US Stock Options Outstanding “Does not reflect proposed reprcing of certain and warrants that is sub
Slide 19: Current Advisory Board Members
Current Advisory Board Members Wayne A. Marasco, M.D, Ph.D. Chairman - Chairman of Scientific Advisory Board, of Cancer and & Al Cancer Institute and Associate Professor of Medicine at Harvard Medical School, He is taking the lead. in ‘expanding 's academic an i as W. Losordo, MD - For many years a
Slide 20: Current Advisory Board Members (Contd.)
Current Advisory Board Members (Contd.) Neil Livingstone, PhD - Dr. Livingstone is currently the Chairman and Chief Executive Officer of ExecutiveAction LLC. He was the founder and, until January, 2007, Chief Executive Officer of lobalOptions Inc., which went publ le is also Le ickson Air-Crane, 200
Slide 21: Investment Summary
Investment Summary Strategic Alliances: Today's revenues from collection, processing & storage are strategic alliances Focused Acquisition Strategy: Focused on acquiring licensing technology and R&D of therapies to provide value for the future. China Expansion: Move will allow a profitable tradition
Slide 22: Contact Information
NeoSteme Contact Information Robin Smith, MD MBA Chairman & CEO Direct: (212) 584-4174 Email: rsmith@neostem.com NeoStem, Inc. 420 Lexington Avenue Suite 450 New York, NY 10170 Main: (212) 584-4180 Fax: (646) 514-7787 www.neostem.com 1.888.STEM BANK Nessiem